An observational study in HYDRADENITIS, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-12.
Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Observational
Prospective, observational cross-sectional study to evaluate the response of patients with HS I-II to monotherapy treatment of topical resorcin 15%, taking into account its safety, impact on quality of life and subclinical evolution.
277 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
This study's planned enrollment of 40 is below the median of 142 across 69 observational studies indexed under Hidradenitis Suppurativa.
Browse Hidradenitis Suppurativa studies →Fundación Pública Andaluza para la gestión de la Investigación en Sevilla is the lead sponsor of 119 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients that suffer from Hs Hurley I-II from the Andalusian Public Health System that are been follow up by the Dermatology Unity of Clinical Management of the HUVM.
Exclusion Criteria:
Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
Evaluate the change in the disease severity
Score change in the Hidradenitis Sartorius modified score
Time frame: Up to 16 weeks
Usage profile
Descriptive measurement of demographic and clinical variables (central tendency, dispersion and distribution of tendencies) prior to the start of treatment.
Time frame: Initial
Evaluate the security of the treatment
Number and description of adverse effects, analysing the percentage and frequency of withdrawal and treatment suspension due to side effects.
Time frame: Up to 16 weeks
Evaluate the changes in the patient´s quailty of life due to the treatment
Quantified by the average absolute change of the dermatology life quality index (DLQI) score, a questionnaire that measures the effect that the skin disease has on the quality of life of an affected person.
Time frame: Up to 16 weeks
Evaluate the changes in the patient´s quailty of life due to the treatment 2
Quantified by the average absolute changein the visual analog scale of pain, odor and suppuration, a scale used to measure the intensity or frequency of the symptoms related to the pain, odor and suppuration of the disease.
Time frame: Up to 16 weeks
Total and partial ultrasound responders frequency of distribution.
Change in number of fistulas, pseudocysts and abscess as well as change in doppler activity. Defining total ultrasound responders as the ones that have a smaller number of pseudocysts, liquid collections, fistulas, smaller size and thickness of the main injury and less doppler activity than the registered in the baseline ultrasound and partial ultrasound responders as the ones that have less activity than in the baseline ultrasound in at least one of the previous variables without increase in any of the others.
Time frame: Up to 16 weeks
Evaluate the frequency of responders
Defining responder as the combination of the decrease in the abscess/nodule count by at least 50% (minimum of one), without increase in the number of draining fistulas and the number of abscesses.
Time frame: Up to 16 weeks
Evaluate the change in the disease severity.
Score change in the Physician Global Assesment scale for Supurative Hidradenitis
Time frame: Up to 16 weeks
This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla